ArticleEuropean journal of medical research2026
Diagnostic and therapeutic significance of exosomal miR-143-5p in the plasma of patients with rheumatoid arthritis.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MicroRNAs as current diagnostic biomarkers and potential therapeutic targets in allergic and non-allergic rhinitis - A functional characterization.Current allergy and asthma reports · 2026Review
- Immunological heterogeneity in rheumatoid arthritis: challenges in early-stage stratification, non-response to targeted therapy, and the restoration of immune tolerance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the expression levels of exosomal microRNA (miRNA) in patients with rheumatoid arthritis (RA) and to assess the diagnostic and therapeutic significance of these biomarkers in the context of RA.
methodsPlasma-derived exosomes were isolated from patients with RA and from healthy control participants, followed by miRNA sequencing. Key differentially expressed miRNAs were initially identified and validated in a pilot cohort and subsequently confirmed in an expanded sample population. An independent t-test was applied to compare miRNA expression profiles between patients with RA and healthy controls, as well as between pre- and post-treatment states in the RA group. The diagnostic utility of selected miRNAs was assessed using receiver operating characteristic (ROC) analysis. Additionally, associations between miRNA expression levels and clinical parameters, including erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP), and C-reactive protein (CRP), was evaluated using Pearson's correlation coefficient.
resultsPlasma exosomal miR-143-5p expression was significantly elevated in patients with RA prior to treatment. Following therapeutic intervention, expression levels of miR-143-5p were not significantly different from those observed in healthy controls. ROC curve analysis demonstrated a high diagnostic value for plasma exosome miR-143-5p, with an area under the curve of 0.918, sensitivity of 93.3% and specificity of 85.7%. Additionally, miR-143-5p levels were positively correlated with clinical inflammatory markers, including ESR, RF, anti-CCP, and CRP.
conclusionPlasma exosomal miR-143-5p demonstrates strong diagnostic potential in individuals with RA and may contribute to the understanding of disease pathogenesis. Modulation of miR-143-5p expression could serve as a valuable biomarker for disease assessment and represents a potential therapeutic in the management of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.